True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, today announced the appointment of James Gilbert, M.D., as the Company’s first Chief Medical Officer (CMO). As CMO, Dr. Gilbert will oversee all clinical development and regulatory activities for the company, as True North advances its lead product candidate, TNT009, into human clinical trials for autoantibody-driven rare diseases that are mediated by the Complement system.
Help employers find you! Check out all the jobs and post your resume.
